Cure My Disease

Don't miss your cure!

 Log in / Sign up

Robot butler could transform ALS care at home and in hospital

NCT ID NCT07572838

Knowledge-focused Sponsor: University of Pisa Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a robot named Alter-Ego to see if it can safely help doctors, nurses, and therapists care for people with ALS. The robot can be controlled remotely or work on its own to do tasks like guiding remote medical visits, delivering supplies, and reminding patients about therapy. About 40 ALS patients and their healthcare team will try out the robot and give feedback on how easy and useful it is.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Alter-Ego humanoid robotic platform
What this could lead to
If successful, this robot could help healthcare teams provide remote check-ups, therapy, and daily support for ALS patients, making care more accessible.
What could go wrong
This is an early observational study with only 40 patients, so results may not apply widely. The robot is not a medical device and does not treat the disease itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 52 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with Amyotrophic Lateral Sclerosis hospitalized in the ALS unit at ICS Maugeri IRCCS, Milan.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* Inclusion Criteria * Healthcare Professionals 1. Age within the legal working age range for professional employment. 2. Experience in the management and treatment of patients affected by motor neuron disease. 3. Expected employment at ICS Maugeri IRCCS, Milan Camaldoli, for the entire duration of the study. 4. Ability to understand and provide informed consent. * Patients 1. Diagnosis of possible, probable, or definite Amyotrophic Lateral Sclerosis (ALS) according to the El Escorial criteria. 2. Adults aged between 18 and 80 years. 3. Ability to understand and provide informed consent. 4. Absence of psychiatric disorders or psychological conditions that, in the physician's judgment, could cause stress during interaction with the robot. \--- * Exclusion Criteria * Healthcare Professionals 1\. Health conditions that, in the clinician's judgment, could make the use of the Alter-Ego system via a head-mounted display unsafe or inappropriate. * Patients 1. Individuals with severe psychiatric disorders or cognitive impairments that compromise the ability to complete assessment scales (based on medical history data). 2. Individuals with moderate to severe cognitive impairment, defined as a score below 81.92 on the ECAS questionnaire (routinely administered during the first days of hospitalization). 3. Individuals in isolation due to infectious causes.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amyotrophic lateral sclerosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amyotrophic lateral sclerosis Health adult subjects

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Istituti Clinici Scientifici Maugeri IRCCS, Milan Institute

    Milan, Milan, 20138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.